Mental Health Access and Provider Support Act of 2026

What happened: Rep. Fitzpatrick (R-PA) and Rep. Tonko (D-NY) introduced HR8081 on March 25, 2026, the Mental Health Access and Provider Support Act of 2026. The bill amends Section 1833(a)(1) of the Social Security Act to raise Medicare Part B mental health service reimbursement from 75% to 85% of the fee schedule amount. It has been referred to two committees (Energy and Commerce, Ways and Means) with no further action. Companion bill S4202 has been introduced in the Senate. The bill is in the earliest legislative stage with zero appropriation. Medicare Advantage impact is neutral per Congressional analysis: higher capitation payments from CMS will offset potential utilization increases. The money trail: This is an authorization bill with no dollar amount attached. It changes the payment formula but does not allocate specific funding. Actual outlays depend on CMS implementation and future appropriations. There is no direct grant or contract mechanism — the bill modifies an existing payment rate for all Medicare-participating mental health providers. Structural winners and losers: The bill primarily benefits community-based psychologists and clinical social workers who treat Medicare patients. Among public companies, only managed care organizations with Medicare Advantage exposure are affected. UnitedHealth Group ($UNH) is the largest Medicare Advantage insurer through its UnitedHealthcare segment and also operates Optum, a behavioral health provider network. The capitation adjustment mechanism makes UNH structurally neutral to the rate change. Humana ($HUM) has high Medicare Advantage concentration but similar neutral exposure. Centene ($CNC) focuses on Medicaid rather than Medicare Advantage, making it minimally affected. Market trends: The market data shows significant recent strength across managed care stocks. UNH has surged 36.34% over 30 days from $324.63 to $368.92. HUM has gained 39.16% over the same period. CNC has rallied 62.37%. These moves appear driven by broader sector dynamics (likely positive Medicare Advantage rate announcements or regulatory relief) rather than this specific early-stage bill. The bill's introduction on March 25 did not trigger a notable stock reaction in any of the three tickers. Timeline: This bill is in committee referral with no hearings scheduled. It must pass both committees, then the House floor, then the Senate (where companion S4202 is also in committee), then survive any conference committee, then be signed into law. The effective date of January 1, 2027 gives nearly 8 months for legislative processing. Given the early stage, single cosponsor status, and lack of appropriation, passage probability is low in the current session. The 119th Congress has approximately 9 months remaining before the 2026 midterm elections, which typically truncates legislative productivity.